Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats

Hepatology

Volumn 59, Issue 6, 2014, Pages 2286-2298

  Verbeke, Len ^a   Farre, Ricard ^b,c   Trebicka, Jonel ^d   Komuta, Mina ^a   Roskams, Tania ^a   Klein, Sabine ^d   Elst, Ingrid Vander ^a   Windmolders, Petra ^a   Vanuytsel, Tim ^b   Nevens, Frederik ^a   Laleman, Wim ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIMETHYLARGININASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FARNESOID X RECEPTOR; OBETICHOLIC ACID; RHO KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL TONE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVITY; HEMODYNAMICS; IN VITRO STUDY; IN VIVO STUDY; INTRAHEPATIC VASCULAR RESISTANCE; INTRAHEPATIC VASCULAR TONE; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER PERFUSION; MALE; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT; SHORT COURSE THERAPY; SIGNAL TRANSDUCTION; STELLATE CELL; UPREGULATION; VASCULAR RESISTANCE; VASODILATATION;

ANIMALS; CHENODEOXYCHOLIC ACID; DISEASE MODELS, ANIMAL; DOWN-REGULATION; DRUG EVALUATION, PRECLINICAL; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; MALE; NITRIC OXIDE SYNTHASE TYPE III; RANDOM ALLOCATION; RATS; RATS, WISTAR; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION;

EID: 84901605121     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26939     Document Type: Article

References (56)

1. Laleman W, Van Landeghem L, Wilmer A, Fevery J, Nevens F. Portal hypertension: from pathophysiology to clinical practice. Liver Int 2005;25:1079-1090.
2. Arsani SK, Kamath PS. Natural history of cirrhosis. Curr Gastroenterol Rep 2013;15:308.
3. Jepsen P, Ott P, Andersen K, Sørensen HT, Vilstrup H. Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology 2010;51:1675-1682.
4. Laleman W, Simon-Talero M, Maleux G, Perez M, Ameloot K, Soriano G, et al. Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. Hepatology 2013;57:2448-2457.
5. Lebrec D, Poynard T, Hillon P, Benhamou JP. Propanolol for the prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study. N Engl J Med 1981;305:1371-1374.
6. Pascal JP, Cales P. Propanolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices. N Engl J Med 1987;317:856-861.
7. Groszmann RJ, Bosch J, Grace ND, Conn HO, Garcia-Tsao G, Navasa M, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 1990;90:1401-1407.
8. Feu F, Garcia-Pagan JC, Bosch J, Luca A, Terés J, Escorsell A, Rodés J. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995;346:1056-1059.
9. Abraldes JG, Tarantino I, Turnes J, Garcia-Pagan JC, Rodés J, Bosch J. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. epatology 2003;37:902-908.
10. Sersté T, Melot C, Francoz C, Durand F, Rautou PE, Valla D, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 2010;52:1017-1022.
11. Garcia-Pagan JC, Gracia-Sancho J, Bosch J. Functional aspects on the pathophysiology of portal hypertension in cirrhosis. J Hepatol 2012;57:458-461.
12. Garcia-Pagan JC, Shah VH. Microparticles and paracrine signaling in portal hypertension: crucial conversations or idle chat. Gastroenterology 2012;143:22-25.
13. Friedman SL, Rockey DC, McGuire RF, Maher JJ, Boyles JK, Yamasaki G. Isolated hepatic lipocytes and Kuppfer cells from normal human liver: morphological and functional characteristics in primary culture. Hepatology 1992:15:234-243.
14. Laleman W, Van Landeghem L, Severi T, Vander Elst I, Zeegers M, Bisschops R, et al. Both Ca2+-dependent and -independent pathways are involved in rat hepatic stellate cell contraction and intrahepatic hyperresponsiveness to methoxamine. Am J Physiol Gastrointest Liver Physiol 2007;292:G556-G564.
15. Rockey DC, Chung JJ. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology 1998;114:344-351.
16. Shah V, Toruner M, Haddad F, Cadelina G, Papapetropoulos A, Choo K, et al. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology 1999;117:1222-1228.
17. Van de Casteele M, Omasta A, Janssens S, Roskams T, Desmet V, Nevens F, Fevery J. In vivo gene transfer of endothelial nitric oxide synthase decreases portal pressure in anaesthetised carbon tetrachloride cirrhotic rats. Gut 2002;51:440-445.
18. Laleman W, Omasta A, Van De Casteele M, Zeegers M, Vander Elst I, Van Landeghem L, et al. A role for asymmetric dimethylarginine (ADMA) in the pathophysiology of portal hypertension in biliary cirrhotic rats. Hepatology 2005;42:1382-1390.
19. Lavina B, Gracia-Sancho J, Rodriguez-Vilarrupla A, Chu Y, Heistad DD, Bosch J, García-Pagán JC. Superoxide dismutase gene transfer reduces portal pressure in CCl4-cirrhotic rats with portal hypertension. Gut 2009;58:118-125.
20. Graupera M, Garcia-Pagan JC, Abraldes JG, Peralta C, Bragulat M, Corominola H, et al. Cyclooxygenase-derived products modulate the increased intrahepatic resistance of cirrhotic rat livers. Hepatology 2003;37:172-181.
21. Laleman W, Van Landeghem L, Van Der Elst I, Zeegers M, Fevery J, Nevens F. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats. Gastroenterology 2007;132:709-719.
22. Klein S, Van Beuge MM, Granzow M, Beljaars L, Schierwagen R, Kilic S, et al. HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects. J Hepatol 2012;57:1220-1227.
23. Vanwijngaerden YM, Wauters J, Langouche L, Vander Perre S, Liddle C, Coulter S, et al. Critical illness evokes elevated circulating bile acids related to altered hepatic transporter and nuclear receptor expression. Hepatology 2010;54:1741-1752.
24. Wang Y, Chen WD, Wang M, Yu D, Forman BM, Huang W. Farnesoid X receptor antagonizes nuclear factor kB in hepatic inflammatory response. Hepatology 2008;48:1632-1643.
25. Fiorucci S, Antonelli E, Rizzo G, Renga B, Mencarelli A, Riccardi L, et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 2004;127:1497-1512.
26. Gadaleta RM, van Erpecum KJ, Oldenburg B, Willemsen EC, Renooij W, Murzilli S, et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 2011;60:463-472.
27. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 2009;89:147-191.
28. Li J, Kuruba R, Wilson A, Gao X, Zhang Y, Li S. Inhibition of endothelin-1 mediated contraction of hepatic stellate cells by FXR ligand. PLoS One 2010;5:e13955.
29. Fickert P, Fuchsbichler A, Moustafa T, Wagner M, Zollner G, Halilbasic E, et al. Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. Am J Pathol 2009;175:2392-2405.
30. Li J, Wilson A, Kuruba R, Gao X, He F, Zhang LM, et al. FXR-mediated regulation of eNOS expression in vascular endothelial cells. Cardiovasc Res 2008;77:169-177.
31. Hu T, Chouinard M, Cox AL, Sipes P, Marcelo M, Ficorilli J, et al. Farnesoid X receptor agonist reduces asymmetric dimethylarginine levels through hepatic dimethylarginine dimethylaminohydrolase-1 gene regulation. J Biol Chem 2006;52:39831-39838.
32. Mookerjee RP, Yago-Baenas M, Mehta G, Beecher-Jones T, Hooshmand-Rad RP, Parihar N, et al. Effect of the FXR agonist obeticholic acid on portal pressure in alcoholic cirrhosis: a phase 2 proof of concept study [abstract]. Hepatology 2012;56(Suppl.):191A-1144A.
33. Laleman W, Vander Elst I, Zeegers M, Servaes R, Libbrecht L, Roskams T, et al. A stable model of cirrhotic portal hypertension in the rat: thioacetamide revisited. Eur J Clin Invest 2006;36:242-249.
34. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008;3:1101-1108.
35. Moleda L, Trebicka J, Dietrich P, Gäbele E, Hellerbrand C, Straub RH, et al. Amelioration of portal hypertension and the hyperdynamic circulatory syndrome in cirrhotic rats by neuropeptide Y via pronounced splanchnic vasoaction. Gut 2011;60:1122-1132.
36. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998;273:24266-24271.
37. Trebicka J, Hennenberg M, Laleman W, Shelest N, Biecker E, Schepke M, et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 2007;46:242-253.
38. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, et al. Identification of a nuclear recptor for bile acids. Science 1999;284:1362-1365.
39. Parks DJ, Blanchard RK, Bledsoe G, Chandra G, Consler TG, Kliewer SA, et al. Bile acids: natural ligands for orphan nuclear receptor. Science 1999;284:1365-1368.
40. Huang W, Ma K, Zhang J, Qatanani M, Cuvillier J, Liu J, et al. Nuclear receptor-dependent bile acid signalling is required for normal liver regeneration. Science 2006;312:233-236.
41. Wolfe A, Thomas A, Edwards G, Jaseja R, Guo GL, Apte U. Increased activation of the Wnt/beta-catenin pathway in spontaneous hepatocellular carcinoma observed in farnesoid X receptor knockout mice. J Pharmacol Exp Ther 2011;388:12-21.
42. Liu Y, Binz J, Numerick MJ, Dennis S, Luo G, Desai B, et al. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J Clin Invest 2003;112:1678-1687.
43. Kong B, Luyendyck JP, Tawfik O, Guo GL. Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet. J Pharmacol Exp Ther 2009;328:116-122.
44. Zhang S, Wang J, Liu Q, Harnish DC. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J Hepatol 2009;51:380-388.
45. Adorini L, Pruzanski M, Shapiro D. Farnesoid-X-receptor targeting to treat nonalcoholic steatohepatitis. Drug Disc Today 2012;17:988-997.
46. Pelliciari R, Fiorucci S, Camaioni E, Clerici C, Costantino G, Maloney PR, et al. 6-alpha-ethyl-chenodeoxycholic acid, a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem 2002;45:3569-3572.
47. Khurana S, Raufman JP, Pallone TL. Bile acids regulate cardiovascular function. Clin Transl Sci 2011;4:210-218.
48. Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 2002;35:478-491.
49. Di Pascoli M, Divi M, Rodriguez-Vilarrupla A, Rosado E, Gracia-Sancho J, Vilaseca M, et al. Resversatrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats. J Hepatol 2012;58:904-910.
50. De Franchis R; Baveno V Faculty. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2010;53:762-768.
51. Gluud LL, Langholz E, Krag A. Meta-analysis: isosorbide-mononitrate alone or with either beta-blockers or endoscopic therapy for the management of oesophageal varices. Aliment Pharmacol Ther 2010;32:859-871.
52. Lu TT, Makishima M, Repa JJ, Schoonjans K, Kerr TA, Auwerx J, et al. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell 2000;6:507-515.
53. Lu CW, Xiong Y, He P. Dimethylarginine dimethylaminohydrolase-2 overexpression improves impaired nitric oxide synthesis of endothelial cells induced by glycated protein. Nitric Oxide 2007;16:94-103.
54. Kajimoto H, Kai H, Aoki H, Yasuoka S, Anegawa T, Aoki Y, et al. Inhibition of eNOS phosphorylation mediates endothelial dysfunction in renal failure: new effect of asymmetric dimethylarginine. Kidney Int 2012;81:762-768.
55. Ghebremariam YT, Yamada K, Lee JC, Johnson CLC, Atzler D, Anderssohn M, et al. FXR Agonist INT-747 Upregulates DDAH expression and enhances insulin sensitivity in high-salt fed Dahl Rats. Plos One 2013;8:e60653.
56. Verbeke L, Nevens F, Laleman W. Bench-to-bedside-review: acute-on-chronic liver failure: linking the gut, liver and systemic circulation. Crit Care 2011;15:233.